Ennature Bio Pharma: The financial results for the period ended September 30, 2026
Ennature Bio Pharma (ENNATURE) filed a disclosure titled "The financial results for the period ended September 30, 2026".
What happened
Ennature Bio Pharma (ENNATURE) filed a disclosure with the exchanges on 12 November 2026 at 01:43 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Ennature Bio Pharma is a listed company in the Healthcare sector.
The stock last traded at ₹203, against a 52-week range of ₹190–₹264.9 (23.4% below the high).
What history shows
BCEIE has no earlier results filing from this company on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.6% over five days; 58% of them rose the next day.
Market-wide, 11,631 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 12 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Ennature Bio Pharma Lists; Plans 6–8 New Branded Nutraceuticals
- IGL Spirits and Ennature Bio Pharma shares to begin trading on Nov 4
- Ennature Bio Pharma Limited lists on NSE and BSE
- Ennature Bio Pharma Ltd. Financials – Balance Sheet, Profit & Loss, Cash Flow
- Ennature Bio Pharma lists on NSE and BSE, targets branded nutraceuticals growth
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.